[{"id":"9c6947a9-7642-44d7-8cde-da7fb3ca0beb","acronym":"","url":"https://clinicaltrials.gov/study/NCT05586360","created_at":"2022-10-19T13:56:32.222Z","updated_at":"2025-02-25T17:31:39.005Z","phase":"Phase 2","brief_title":"T-reg Function Changes: a Novel Immune Regulatory Effect Underlying Benefit of Statin Use on Lethal Prostate Cancer","source_id_and_acronym":"NCT05586360","lead_sponsor":"Medical University of South Carolina","biomarkers":" FOXP3","pipe":"","alterations":" ","tags":["FOXP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e simvastatin"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 03/11/2024","start_date":" 03/11/2024","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2025-01-30"},{"id":"7cc580e8-c1f3-4929-85f2-d9ad42d412c9","acronym":"","url":"https://clinicaltrials.gov/study/NCT02968810","created_at":"2021-01-18T14:35:38.364Z","updated_at":"2024-07-02T16:35:09.555Z","phase":"Phase 2","brief_title":"Simvastatin in Preventing Liver Cancer in Patients With Liver Cirrhosis","source_id_and_acronym":"NCT02968810","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" AFP","pipe":" | ","alterations":" ALPL-H","tags":["AFP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALPL-H"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e simvastatin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 59","initiation":"Initiation: 06/21/2017","start_date":" 06/21/2017","primary_txt":" Primary completion: 05/03/2023","primary_completion_date":" 05/03/2023","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-04-16"},{"id":"1ce44e77-8bde-42ee-b343-687c33a5fa41","acronym":"SIMPHONY","url":"https://clinicaltrials.gov/study/NCT03324425","created_at":"2021-01-18T16:25:00.670Z","updated_at":"2024-07-02T16:35:23.419Z","phase":"Phase 2","brief_title":"Simvastatin Plus Dual Anti-HER2 Therapy for Metastatic Breast Cancer","source_id_and_acronym":"NCT03324425 - SIMPHONY","lead_sponsor":"Baylor Breast Care Center","biomarkers":" ER","pipe":" | ","alterations":" HER-2 positive","tags":["ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e simvastatin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 5","initiation":"Initiation: 03/04/2020","start_date":" 03/04/2020","primary_txt":" Primary completion: 12/01/2028","primary_completion_date":" 12/01/2028","study_txt":" Completion: 12/01/2030","study_completion_date":" 12/01/2030","last_update_posted":"2024-01-15"},{"id":"97d926d0-be37-423b-83a2-cb239072fda6","acronym":"","url":"https://clinicaltrials.gov/study/NCT05464810","created_at":"2022-07-19T14:54:34.432Z","updated_at":"2024-07-02T16:35:27.090Z","phase":"Phase 1","brief_title":"Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer","source_id_and_acronym":"NCT05464810","lead_sponsor":"Emory University","biomarkers":" HER-2 • ER • PGR • IL6 • TNFA • IL10 • TGFB1","pipe":" | ","alterations":" HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive","tags":["HER-2 • ER • PGR • IL6 • TNFA • IL10 • TGFB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e letrozole • simvastatin"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 09/02/2022","start_date":" 09/02/2022","primary_txt":" Primary completion: 04/15/2025","primary_completion_date":" 04/15/2025","study_txt":" Completion: 04/15/2025","study_completion_date":" 04/15/2025","last_update_posted":"2023-12-05"},{"id":"3f7300d8-189d-4a32-8198-659823018d3e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03454529","created_at":"2021-02-22T06:52:45.002Z","updated_at":"2024-07-02T16:35:41.405Z","phase":"Phase 2","brief_title":"The Effect of Simvastatin on Breast Cancer Cell Growth in Women With Stage I-II Breast Cancer","source_id_and_acronym":"NCT03454529","lead_sponsor":"Michael Simon","biomarkers":" HER-2 • PGR","pipe":"","alterations":" ","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e simvastatin"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 03/09/2018","start_date":" 03/09/2018","primary_txt":" Primary completion: 10/06/2021","primary_completion_date":" 10/06/2021","study_txt":" Completion: 10/06/2021","study_completion_date":" 10/06/2021","last_update_posted":"2023-08-01"},{"id":"92a218df-d6c0-44fe-8a39-9c050b9e66de","acronym":"","url":"https://clinicaltrials.gov/study/NCT05550415","created_at":"2022-09-22T13:55:23.932Z","updated_at":"2024-07-02T16:36:03.476Z","phase":"Phase 2","brief_title":"The Role of Simvastatin in The Epithelial-Mesenchymal Transition Process of Breast Cancer","source_id_and_acronym":"NCT05550415","lead_sponsor":"Indonesia University","biomarkers":" VIM","pipe":" | ","alterations":" VIM expression","tags":["VIM"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VIM expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e simvastatin"],"overall_status":"Recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 08/19/2022","start_date":" 08/19/2022","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 02/01/2025","study_completion_date":" 02/01/2025","last_update_posted":"2022-09-26"},{"id":"315e894b-0d1b-4d38-8c6b-e53b589b4266","acronym":"","url":"https://clinicaltrials.gov/study/NCT01156545","created_at":"2022-04-07T06:53:13.464Z","updated_at":"2024-07-02T16:36:13.884Z","phase":"Phase 2","brief_title":"BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC","source_id_and_acronym":"NCT01156545","lead_sponsor":"National Cancer Center, Korea","biomarkers":" IGFBP3","pipe":" | ","alterations":" EGFR mutation","tags":["IGFBP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gilotrif (afatinib) • simvastatin"],"overall_status":"Completed","enrollment":" Enrollment 68","initiation":"Initiation: 10/01/2010","start_date":" 10/01/2010","primary_txt":" Primary completion: 12/31/2016","primary_completion_date":" 12/31/2016","study_txt":" Completion: 06/09/2021","study_completion_date":" 06/09/2021","last_update_posted":"2022-04-06"},{"id":"9d269c50-cc6c-43a1-8de6-02054f537371","acronym":"","url":"https://clinicaltrials.gov/study/NCT04985201","created_at":"2021-08-02T14:52:59.493Z","updated_at":"2024-07-02T16:36:26.746Z","phase":"Phase 2","brief_title":"Combined Simvastatin and Irinotecan in Treating ES-SCLC Patients Relapsed From 1st Chemotherapy","source_id_and_acronym":"NCT04985201","lead_sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","biomarkers":" ALK • ROS1","pipe":" | ","alterations":" ALK rearrangement","tags":["ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e irinotecan • simvastatin"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 11/01/2021","start_date":" 11/01/2021","primary_txt":" Primary completion: 12/01/2022","primary_completion_date":" 12/01/2022","study_txt":" Completion: 08/01/2023","study_completion_date":" 08/01/2023","last_update_posted":"2021-08-09"},{"id":"1bc77412-1b12-4c06-b2d8-c2e0007f9660","acronym":"","url":"https://clinicaltrials.gov/study/NCT04698941","created_at":"2021-01-19T20:50:04.276Z","updated_at":"2024-07-02T16:36:27.285Z","phase":"Phase 2","brief_title":"Combined Simvastatin and Albumin Paclitaxel in Treating ES-SCLC Patients Relapsed From 1st Chemotherapy","source_id_and_acronym":"NCT04698941","lead_sponsor":"Shanghai Pulmonary Hospital, Shanghai, China","biomarkers":" ALK • ROS1","pipe":" | ","alterations":" ALK rearrangement","tags":["ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • albumin-bound paclitaxel • simvastatin"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 07/25/2021","start_date":" 07/25/2021","primary_txt":" Primary completion: 12/30/2021","primary_completion_date":" 12/30/2021","study_txt":" Completion: 12/30/2022","study_completion_date":" 12/30/2022","last_update_posted":"2021-07-29"},{"id":"fbf421ef-b893-4cba-ab92-9bfe9c4053dd","acronym":"","url":"https://clinicaltrials.gov/study/NCT04705909","created_at":"2021-01-19T20:51:31.076Z","updated_at":"2024-07-02T16:36:36.216Z","phase":"Phase 2/3","brief_title":"Efficacy of Statin Addition to Neoadjuvant Chemotherapy Protocols for Breast Cancer","source_id_and_acronym":"NCT04705909","lead_sponsor":"Mansoura University","biomarkers":" CCND1 • CASP3","pipe":"","alterations":" ","tags":["CCND1 • CASP3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e simvastatin • pitavastatin"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 01/15/2021","start_date":" 01/15/2021","primary_txt":" Primary completion: 09/15/2021","primary_completion_date":" 09/15/2021","study_txt":" Completion: 12/15/2021","study_completion_date":" 12/15/2021","last_update_posted":"2021-01-12"},{"id":"65879970-940d-49a4-bf2d-eb502d2401a1","acronym":"AflacST1402","url":"https://clinicaltrials.gov/study/NCT02390843","created_at":"2021-01-18T11:23:57.025Z","updated_at":"2024-07-02T16:36:46.711Z","phase":"Phase 1","brief_title":"Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors","source_id_and_acronym":"NCT02390843 - AflacST1402","lead_sponsor":"Emory University","biomarkers":" STAT3 • IL6R","pipe":"","alterations":" ","tags":["STAT3 • IL6R"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • topotecan • simvastatin • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 13","initiation":"Initiation: 02/01/2015","start_date":" 02/01/2015","primary_txt":" Primary completion: 09/22/2019","primary_completion_date":" 09/22/2019","study_txt":" Completion: 09/22/2019","study_completion_date":" 09/22/2019","last_update_posted":"2020-04-03"},{"id":"ceb13093-b87d-4535-863c-5b1f5ec5c206","acronym":"","url":"https://clinicaltrials.gov/study/NCT03086291","created_at":"2021-01-18T15:12:19.020Z","updated_at":"2024-07-02T16:36:52.025Z","phase":"Phase 1","brief_title":"A Phase I Study of High Dose Simvastatin in Patients With Gastrointestinal Tract Cancer Who Failed to Standard Chemotherapy","source_id_and_acronym":"NCT03086291","lead_sponsor":"Samsung Medical Center","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS wild-type • RAS wild-type • NRAS wild-type","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS wild-type • RAS wild-type • NRAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e simvastatin"],"overall_status":"Unknown status","enrollment":" Enrollment 9","initiation":"Initiation: 01/04/2018","start_date":" 01/04/2018","primary_txt":" Primary completion: 09/01/2020","primary_completion_date":" 09/01/2020","study_txt":" Completion: 12/01/2020","study_completion_date":" 12/01/2020","last_update_posted":"2019-12-30"},{"id":"6ade9ced-a0bd-435e-8f76-f6396c330104","acronym":"","url":"https://clinicaltrials.gov/study/NCT02285738","created_at":"2021-01-18T10:46:13.265Z","updated_at":"2024-07-02T16:36:59.833Z","phase":"Phase 1","brief_title":"Anti-Platelet and Statin Therapy to Prevent Cancer-Associated Thrombosis","source_id_and_acronym":"NCT02285738","lead_sponsor":"Case Comprehensive Cancer Center","biomarkers":" HGF • CD40LG","pipe":"","alterations":" ","tags":["HGF • CD40LG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e simvastatin"],"overall_status":"Completed","enrollment":" Enrollment 17","initiation":"Initiation: 12/30/2014","start_date":" 12/30/2014","primary_txt":" Primary completion: 07/17/2017","primary_completion_date":" 07/17/2017","study_txt":" Completion: 10/01/2018","study_completion_date":" 10/01/2018","last_update_posted":"2019-05-08"},{"id":"3a5ad6ea-61b6-488b-86fa-abe4728121ec","acronym":"","url":"https://clinicaltrials.gov/study/NCT00334542","created_at":"2021-01-18T01:09:14.457Z","updated_at":"2024-07-02T16:37:00.993Z","phase":"Phase 2","brief_title":"Simvastatin in Preventing a New Breast Cancer in Women at High Risk for a New Breast Cancer","source_id_and_acronym":"NCT00334542","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" ER • CCND2 • RASSF1 • CRP","pipe":"","alterations":" ","tags":["ER • CCND2 • RASSF1 • CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e simvastatin"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 03/01/2006","start_date":" 03/01/2006","primary_txt":" Primary completion: 06/01/2009","primary_completion_date":" 06/01/2009","study_txt":" Completion: 11/01/2011","study_completion_date":" 11/01/2011","last_update_posted":"2019-04-03"},{"id":"8398ca2b-106a-4a9c-86a7-3c2761a86cd0","acronym":"","url":"https://clinicaltrials.gov/study/NCT00572468","created_at":"2021-01-18T02:05:24.697Z","updated_at":"2024-07-02T16:37:19.929Z","phase":"","brief_title":"Statin Therapy Versus Placebo Prior to Prostatectomy","source_id_and_acronym":"NCT00572468","lead_sponsor":"VA Office of Research and Development","biomarkers":" AR","pipe":"","alterations":" ","tags":["AR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e simvastatin"],"overall_status":"Completed","enrollment":" Enrollment 42","initiation":"Initiation: 12/01/2007","start_date":" 12/01/2007","primary_txt":" Primary completion: 04/01/2013","primary_completion_date":" 04/01/2013","study_txt":" Completion: 04/30/2017","study_completion_date":" 04/30/2017","last_update_posted":"2017-07-13"},{"id":"06f7b1d1-ddd2-45ef-bd0e-16e32b2cdc11","acronym":"","url":"https://clinicaltrials.gov/study/NCT02360618","created_at":"2022-06-02T11:57:09.823Z","updated_at":"2024-07-02T16:37:30.763Z","phase":"Phase 2","brief_title":"Metformin and Simvastatin Use in Bladder Cancer","source_id_and_acronym":"NCT02360618","lead_sponsor":"London Health Sciences Centre","biomarkers":" PTEN","pipe":"","alterations":" ","tags":["PTEN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e metformin • simvastatin"],"overall_status":"Unknown status","enrollment":" Enrollment 44","initiation":"Initiation: 10/01/2015","start_date":" 10/01/2015","primary_txt":" Primary completion: 01/01/2018","primary_completion_date":" 01/01/2018","study_txt":" Completion: 01/01/2018","study_completion_date":" 01/01/2018","last_update_posted":"2016-07-11"}]